We purposed to clarify the contribution of fatty acid transport protein 1 (FATP1/SLC 27A1) to the supply of docosahexaenoic acid (DHA) to the brain across the blood-brain barrier in this study. brain sections showed that FATP1 protein is preferentially localized at the basal membrane of brain microvessel endothelial cells. We found that two neuroprotective substances, taurine and biotin, in addition to DHA, undergo FATP1-mediated efflux. Overall, our results suggest that FATP1 localized at the basal membrane of brain microvessels contributes to the transport of DHA, taurine and biotin into the brain, and insulin rapidly increases DHA supply to the brain by promoting translocation of FATP1 to the membrane.
To maintain the brain function adequately, various nutrients including fatty acids are imported from blood to the brain across the blood-brain barrier (BBB). Docosahexaenoic acid (DHA) is an essential polyunsaturated fatty acid and has neuroprotective effects on cognitive function and memory (Yurko-Mauro et al. 2015) . A decreased level of DHA in the brain is associated with the development of neurodegenerative diseases, such as Alzheimer's disease (Astarita et al. 2010) . Therefore, DHA appears to play a key role in maintaining the functional integrity of the central nervous system (Catalan et al. 2002; Hashimoto et al. 2005; Lim et al. 2005; Hooijmans et al. 2009) .
Although the synthesis ability of DHA from fatty acid precursors in brain is limited, the brain contains large amounts of DHA (Innis 2007) , because DHA is actively imported into the brain across the BBB (Rapoport 2001; Rapoport et al. 2007) , apparently in both phospholipidconjugated and unesterified forms (Thies et al. 1994; Rapoport et al. 2011) . Recently, the orphan transporter mfsd2a was shown to transport lysophosphatidylcholine-DHA from blood to the brain, but it does not transport unesterified DHA at the mouse BBB (Nguyen et al. 2014) . However, a decrease of unesterified DHA in blood can cause a decrease of DHA level in the brain (Gazzah et al. 1995) . Therefore, the influx transport of unesterified DHA across the BBB could also contribute to maintaining an adequate DHA level in brain. The influx transport consists of three steps: (i) uptake of DHA from blood into endothelial cells across the apical membrane, (ii) intracellular transport, and (iii) efflux from endothelial cells into the brain across the basal membrane. It has been reported that an intracellular cell carrier protein, fatty acid binding protein 5 (FABP5), binds unesterified DHA and is involved in its intracellular transport from the apical to basal side of brain microvessel endothelial cells (Pan et al. 2015) . However, the molecular mechanisms that have a responsibility for DHA transport across the apical and basal membranes have yet to be fully clarified.
It has been reported that fatty acid transport protein 1 (FATP1/SLC27A1) is expressed at the human, mouse and porcine BBB using isolated brain microvessels by quantitative targeted absolute proteomic (QTAP) analysis (Shawahna et al. 2011; Uchida et al. 2014; Kubo et al. 2015) . FATP1 is a transporter of various long-chain fatty acids, such as oleic acid (Mitchell et al. 2009 (Mitchell et al. , 2011 Holloway et al. 2011) . Indeed, FATP1 contributes to oleic acid transport in both the apical-to-basal and basal-to-apical directions in primary human brain microvessel endothelial cells (Mitchell et al. 2009 ).
Based on these reports, we hypothesized that (i) FATP1 contributes to DHA transport across the plasma membrane of brain microvessel endothelial cells. Furthermore, since DHA is thought to be mainly absorbed from the diet and effectively supplied to the brain, we also hypothesized that (ii) a dietinduced increase of insulin facilitates the supply of DHA to the brain via FATP1 at the BBB. In this study, we purposed to empirically test these hypotheses. Our results confirm that FATP1 is involved in DHA transport at the basal membrane, and we also found that FATP1 mediates transport of two neuroprotective substances, taurine and biotin, from blood to the brain. Further, insulin promotes DHA uptake by inducing FATP1 trafficking to the plasma membrane.
Materials and methods

Animals and reagents
Male C57BL/6 mice (6-7 weeks of age) were purchased from Japan SLC (Hamamatsu, Japan). The mice were maintained on a 12 h light/dark cycle in a temperature-controlled environment with free access to food and water but they were denied access to food for 16 h before the experiments. ]-biotin was measured using cells. Cells were washed twice with 400 lL extracellular fluid (ECF) buffer, and pre-incubated with 200 lL ECF buffer for 10 min at 37°C. The composition and pH of the ECF buffer was described previously . Quantitative real-time PCR analysis hCMEC/D3 cells were treated with siRNA targeted to FATP1 (FATP1 siRNA) or Stealth RNAi TM siRNA Negative Control Med GC Duplex (Negative control siRNA) purchased from Invitrogen. See Appendix S1 for details. We extracted total RNA from hCMEC/D3 cells using an RNeasy kit (Qiagen, Tokyo, Japan) according to the manufacturer's protocol. Quantitative real-time PCR analysis was performed using an ABI PRISM 7700 sequence detector system (PE Applied Biosystems, Foster City, CA, USA) with 29 SYBR Green PCR Master Mix (PE Applied Biosystems) according to the manufacturer's instructions. This enabled standardization of the initial mRNA content of hCMEC/D3 cells relative to the amount of b-actin. The sequences of the primers for FATP1 and b-actin and the PCR conditions for FATP1 and b-actin are described in the Appendix S1. The mRNA level of FATP1 was normalized by that of b-actin. The relative mRNA level of FATP1 was determined with the 2
ÀDDct method, where Ct is the threshold cycle (Livak and Schmittgen 2001) .
Western blot analysis
Preparation of the whole-cell fraction of hCMEC/D3 cells was performed with cells cultured for 6 days after seeding on 10-cm dishes. Culture medium was removed, the cells were washed twice with 5 mL of phosphate-buffered saline (PBS), and then 2 mL of PBS was added. Cells were scraped from culture dishes, and centrifuged at 230 g for 5 min at 4°C. PBS was quickly removed, and the cells were suspended in 2 mL of suspension buffer (10 mM Tris-HCl (pH 7.4), 250 mM sucrose, 1 mM EDTA) with protease inhibitor cocktail (Sigma Chemical Co, St. Louis, MI, USA) to give a final concentration of 1%. The protein amount of samples was measured by the Lowry method, using the DC protein assay reagent (Bio-Rad). The protein content of the samples was determined by the Lowry method with BSA as a standard. Whole-cell fraction samples were lysed with lysis buffer (5% 2-mercaptoethanol, 2% sodium dodecyl sulfate, 62.5 mM Tris-HCl (pH 6.8), 5% sucrose, 0.002% Bromophenol blue) at 95°C for 5 min, and then immediately stored on ice. Western blot analysis of FATP1 and b-actin in whole-cell fraction was performed. See Appendix S1 for details.
Immunostaining analysis of hCMEC/D3 cells hCMEC/D3 cells were seeded at a density of 5.0 9 10 4 cells/well onto 1.7 cm 2 BD Biocoat TM 4-well culture slides (Corning, NY, USA) coated with collagen type I and cultured for 6 days after the 3rd passage, then immunostaining of FATP1 was performed. Quantitative relative metabolomic analysis of FATP1-expressing and mock HEK293 cells FATP1-expressing HEK293 cells and mock HEK293 cells were cultured on 10-cm dishes after the 3rd passage. When the cells reached confluence, the dishes were washed with 2.0 mL of 5% (w/ w) mannitol in water. Cells were scraped into 1.3 mL of methanol containing 10 lM each of 2 internal standards (ISC1 and ISA1), and diluted with methanol containing 10 lM each of ISC1 and ISA1 to 5.0 9 10 6 cells/mL. All samples were stored for a few days at À80°C until analysis. Samples were then sent for liquid chromatography time-of-flight mass spectrometry (LC-TOFMS) and capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS) analysis to Human Metabolome Technologies Inc. (Tsuruoka, Yamagata, Japan). Metabolome measurement was performed by Human Metabolome Technologies Inc. See Appendix S1 for details.
Immunohistochemical analysis of mouse brain C57BL/6 mice were anesthetized by intraperitoneal injection of pentobarbital, and transcardially perfused with 4% PFA in PBS (pH 7.4) for 5 min under anesthesia to remove blood, then the brain was excised, and the cerebrum was fixed in 4% PFA in PBS for 15 min at 15-25°C. Each cerebrum was cut into per 50 lm thick with a Leica VT 1000S (Leica) in PBS. Immunostaining of FATP1 and GLUT1 was performed. See Appendix S1 for details.
Statistical analysis
Unless otherwise indicated, all data are the mean AE SEM. Statistical significance of differences between the means was determined using the unpaired Student's t-test for two groups and one-way analysis of variance followed by Tukey's post hoc test for more than two groups; and p values less than 0.05 were considered statistically significant. No sample size calculation was performed in this study.
No randomization was performed in this study. No blinding was performed in this study.
Results
Uptake of DHA by FATP1-expressing HEK293 cells and mock HEK293 cells The presence of a high level of FATP1 protein in FATP1-expressing HEK293 cells was confirmed by western blot analysis, and the protein was shown to be preferentially localized in the plasma membrane by immunostaining ( Figure S1 ). Uptake study confirmed that oleic acid, a substrate of FATP1, is significantly taken up by FATP1-expressing HEK293 cells compared to mock HEK293 cells ( Figure S1 ).
To investigate whether DHA is incorporated into cells via FATP1, [ 14 C]-DHA uptake experiments were performed using FATP1-expressing and mock HEK293 cells (Fig. 1) . In FATP1-expressing HEK293 cells, the uptake of [ 14 C]-DHA was significantly higher than that by mock HEK293 cells at both 5 min and 30 min (Fig. 1a) . Treatment with 2 mM oleic acid, a substrate and inhibitor of FATP1 reduced the FATP1-dependent transport of [
14 C]-DHA by 79% (Fig. 1b) .
Carrier-mediated uptake of DHA by hCMEC/D3 cells We investigated whether DHA is incorporated into human brain capillary endothelial cells via a carrier-mediated transport system by a cellular uptake study using hCMEC/D3, an immortalized human brain capillary endothelial cell line (Fig. 2) . To determine an appropriate time frame to evaluate carrier-mediated transport, the time dependence of [ 14 C]-DHA uptake was examined. The uptake amount in hCMEC/D3 cells increased linearly up to 5 min (Fig. 2a) , and therefore uptake at 5 min was ]-DHA/fatty acid free-BSA at 1 : 1 molar ratio) at 37°C for 30 min was measured in the absence (control, open column) and in the presence of 2 mM oleic acid (closed column). The transport amount via FATP1 was expressed as FATP1-dependent transport, which was calculated as the C/M ratio (lL/mg protein) of FATP1-expressing HEK293 cells minus the C/M ratio (lL/mg protein) of mock HEK293 cells. Each column represents the mean AE SEM. The SEM was calculated according to the law of propagation of error (n = 8). ***p < 0.001, significantly different from the control group (Student's t-test). measured in the following experiments. We found that treatment with 1 mM unlabeled DHA and oleic acid reduced the uptake of [ 14 C]-DHA by 86.1% and 38.2%, respectively ( Fig. 2b and c) , and treatment with 1 mM unlabeled DHA reduced the uptake of [ 3 H]-oleic acid by 38.6%, (Fig. 2d) . These results suggested that DHA is incorporated into human brain capillary endothelial cells via a carrier-mediated transport system that is shared with oleic acid.
Contribution of FATP1 to uptake of DHA by hCMEC/D3 cells To investigate the involvement of FATP1 in the incorporation of DHA into human brain capillary endothelial cells, [ 14 C]-DHA uptake was examined under conditions of FATP1 suppression by siRNA treatment (Fig. 3) . RT-PCR experiments were performed to confirm suppression of FATP1 at the mRNA level. A 689 bp fragment was amplified from the cDNA of hCMEC/D3 cells, using primers specific for FATP1 ( Figure S2 ). The mRNA level of FATP1 ]-oleic acid/fatty acid free-BSA at 1 : 1 molar ratio) at 37°C for 1 min was measured in the absence (control, open column) and in the presence of 1 mM DHA (closed column). Uptake was expressed as the cell/medium ratio (lL/mg protein), calculated by dividing the cellular uptake amount (mol/mg of protein) by the test substrate concentration in the uptake medium (mol/ L). The uptake is shown as percent of the C/M ratio in the control group. Each point and column represent the mean AE SEM (n = 4). **p < 0.01 and ***p < 0.001, significantly different from the control group (Student's t-test).
was normalized by that of b-actin in hCMEC/D3 cells. Treatment of hCMEC/D3 cells with FATP1 reduced the transcript levels of FATP1 by 46.2% of that of cells treated with negative control siRNA (Fig. 3a) . In western blot analysis, FATP1 and b-actin proteins were detected at 71 and 42 kDa in the whole-cell fraction of hCMEC/D3 cells, respectively (Fig. 3b) , and the band intensity of FATP1 protein normalized by that of b-actin protein was significantly decreased by 53.2% in cells treated with FATP1 siRNA (Fig. 3c) . We found that the treatment of FATP1 siRNA reduced the 5 and 20 min uptakes of [ 14 C]-DHA by 31.5% and 38.9%, respectively (Fig. 3d) . We calculated the contribution of FATP1 to the total uptake of DHA for 5 min and 20 min in hCMEC/D3 cells was 59.2% and 73.0%, respectively, by dividing the reduction in uptake (31.5% and 38.9%) by that of the protein expression level (53.2%).
Effect of insulin on the uptake of DHA and oleic acid by hCMEC/D3 cells Next, we examined the effect of insulin on the incorporation of DHA and oleic acid and the intracellular localization of FATP1 in hCMEC/D3 cells (Fig. 4) . hCMEC/D3 cells were 
]-DHA/fatty acid free-BSA at 1 : 1 molar ratio) was measured at 37°C for 5 min and 20 min, using hCMEC/D3 cells treated with negative control siRNA (open circles) or FATP1 siRNA (closed circles). Uptake was expressed as the cell/ medium ratio (lL/mg protein), calculated by dividing the cellular (mol/ mg of protein) by the test substrate concentration in the uptake medium (mol/L). Each point represents the mean AE SEM (n = 4). *p < 0.05, **p < 0.01 and ***p < 0.001, significantly different from the negative control siRNA group (Student's t-test).
pre-incubated in EBM-2 medium without or with insulin for 30 min at 37°C, and then the EBM-2 medium was removed. The cells were washed with ECF buffer and immediately used for uptake experiments. In the case of immunostaining, the cells were washed with PBS and used immediately. Pretreatment with 50 nM and 5 lM insulin significantly increased the uptakes of [ 3 H]-oleic acid by 1.16-fold and 1.27-fold, respectively, compared to the control (Fig. 4a) , while the uptakes of [ 14 C]-DHA were significantly increased by 1.55-fold and 1.92-fold, respectively (Fig. 4b) . The localization of FATP1 in hCMEC/D3 cells was examined by immunostaining (Fig. 4c) . In hCMEC/D3 cells without insulin treatment, the immunoreactivity of FATP1 was detected at the cell surface as well as in the intracellular space ( Fig. 4c(i) , green). Double immunostaining with anti-FATP1 antibody (Fig. 4c(i) , green) and propidium iodide, a nuclear marker (Fig. 4c(ii), red) , showed that the immunoreactivity of FATP1 was located outside cell nuclei (Fig. 4c  (iii), green) . Treatment with 50 nM insulin increased the immunoreactivity of FATP1 at the cell surface compared with the control (Fig. 4c(iv), green) . In addition to immunostaining, the QTAP approach was applied to quantitatively examine the insulin-dependent translocation of FATP1 protein from the intracellular space to the plasma membrane in hCMEC/D3 cells (Table S1 ). Insulin treatment did not change the protein expression level of FATP1 in whole-cell fraction, but decreased it by 72% in the crude membrane fraction including the intracellular membranes, and increased it in the plasma membrane fraction by 201%. These results suggest that the insulin facilitates the uptake transport of both DHA and oleic acid by translocating FATP1 protein from intracellular space to plasma membrane in human cerebral microvessel endothelial cells.
Comparison of intracellular DHA concentration in FATP1-expressing and mock HEK293 cells
To investigate the preferred direction of DHA transport by FATP1 in the steady state, FATP1-expressing and mock HEK293 cells were cultured in normal culture medium, and the intracellular DHA concentrations at the steady state were compared by means of relative metabolomic analysis with CE-TOFMS and LC-TOFMS. Based on their m/z values and migration times, 212 metabolites were detected in FATP1-expressing and mock HEK293 cells (Table S2 ). The DHA concentration in FATP1-expressing HEK293 cells was 1.92-fold smaller than that in mock HEK293 cells, suggesting that FATP1 contributes predominantly to the efflux transport of DHA in the steady-state environment. Among the other 211 metabolites detected in the present metabolomic analysis, 60% showed < 1.5-fold difference between FATP1-expressing HEK293 cells and mock HEK293 cells. Kubo et al. (2015) have found that FATP1 protein is preferentially expressed at the basal membrane rather than the apical membrane in brain microvessels by means of a combination of plasma membrane fractionation and QTAP techniques. However, this localization has not been validated by antibody-based analysis. Therefore, we examined the localization of FATP1 in mouse brain microvessels using immunohistochemical methods. When brain sections of C57BL/6 mice were stained with anti-FATP1 antibody (Fig. 5) , the immunoreactivity showed a circular form (Fig. 5a, green, arrow) . We also stained brain sections of C57BL/6 mice with anti-GLUT1 antibody as a marker of apical and basal membranes in brain microvessel endothelial cells. Double immunostaining with anti-FATP1 antibody ( Fig. 5b and d, green) and anti-GLUT1 antibody ( Fig. 5c and d, red) showed that FATP1 staining overlapped with GLUT1 staining on the outer side of microvessels, but not on the inner side (Fig. 5d, yellow) . No significant fluorescence was observed in brain microvessels stained with normal rabbit and mouse IgG (data not shown). These results indicate that FATP1 protein is preferentially localized at the basal membrane of brain microvessels.
Immunohistochemical analysis of FATP1 in mouse brain
Taurine and biotin transport via FATP1
To maintain adequate brain function, the brain needs to import various nutrients, the neuroprotective compound taurine and the vitamin biotin, from blood through the BBB. Although taurine is supplied via taurine transporter (TauT/SLC6A6) at the BBB in rodents (Kang et al. 2002) , the protein expression level of TauT in human BBB is far smaller than that in mouse BBB . FATP1 is commonly expressed at both mouse and human BBB (Shawahna et al. 2011; Uchida et al. 2014) . Biotin is taken up from blood into the brain capillary endothelial cells via Na + -dependent multivitamin transporter (SMVT/ SLC5A6) at the apical membrane . However, the efflux transport mechanism across the basal membrane, which is also essential for supply of biotin to the brain, remains unknown. Therefore, we examined whether taurine and biotin are transported by FATP1, which is localized at the basal membrane (Fig. 5). [ Discussion This study is the first to establish that FATP1 plays a major role in DHA transport at the plasma membrane of human brain microvessel endothelial cells, and that DHA transport is facilitated by insulin. We also show that FATP1 is expressed at the basal membrane in brain microvessels, and plays an important role in intracellular-to-extracellular DHA transport. Thus, FATP1 appears to be a major component of the homeostatic mechanisms that regulate transfer to the brain of DHA derived from the diet. We further found that FATP1 transports not only DHA, but also two neuroprotective substances, taurine and biotin. Therefore, FATP1 may also contribute to the supply of taurine and biotin to the brain. These findings indicate that FATP1 is not merely a transporter of long-chain fatty acids at the BBB, but also plays a key role in supplying a variety of neuro-supportive substances to the brain.
In the uptake study of [ 3 H]-oleic acid in the incubation medium. The unbound fraction (fu) was estimated using equilibrium dissociation constants (K d ) and maximum binding (B max ) from the equation (Toutain and Bousquet-Melou 2002) .
B max to BSA in plasma (B max, plasma ) was estimated using the K d value and the unbound fraction in plasma (fu , plasma ) from the equation.
The K d values of DHA and oleic acid for BSA were reported to be 29 and 6.6 nM, respectively. Bojesen 1994, 1998) . The plasma protein-binding ratios of DHA and oleic acid were 99.9% (fu plasma = 0.001) and 99% (fu plasma = 0.01), respectively (Spector et al. 1969; Bessonneau et al. 2015) . The B max, plasma of DHA and oleic acid were 29.0 lM and 653 nM with Eq. 2, respectively.
The unbound fraction in the incubation medium (fu incubation medium ) was estimated from the equation.
The B max to BSA in the incubation medium (B max, incubation medium ) was also estimated from the equation for the BSA concentration in plasma (C plasma ) and the BSA concentration in the incubation medium (C incubation medium ).
The BSA concentration in plasma (C plasma ) was 500 lM. In this uptake study, fatty acid free-BSA was added to the incubation buffer at a 1 : 1 molar ratio with respect to [ 3 H]-oleic acid was 33-68% and 99.8%, respectively, from Eq.4.
In the knock-down analysis of FATP1 in hCMEC/D3 cells, we showed FATP1-dependent uptake contributed to the uptake of [
14 C]-DHA in hCMEC/D3 cells (Fig. 3) . However, there are large differences in the C/M ratio of [ 14 C]-DHA between FATP1-expressing HEK293 cells and hCMEC/D3 cells (Fig 1 and 2) . We believe that FATP1 may need co-factors to facilitate its transport and this was the cause of these differences. FATP1 has been reported to be expressed at mitochondria, and form a complex with carnitine palmitoyltransferase I, which transports the cytosol acyl-CoA into mitochondria (Sebastian et al. 2009 ). Mitochondrial FATP1 has also been reported to increase 2-oxoglutarate dehydrogenase activity (Wiczer et al. 2009) , and to couple with diglyceride acyltransferase 2 in vesicles for the diffusion of lipid droplets (Xu et al. 2012) . Based on these previous reports, we believe that the FATP1 at the plasma membrane may need co-factors to transport its substrates, and the co-factors may be expressed in hCMEC/ D3 cells, but not in FATP1-expressing HEK293 cells. The western blot in this study did not show a completely clear band for FATP1 protein and, so, it would in future be better to obtain a clearer result in western blot analysis, using another FATP1 antibody with better reactivity.
It is crucial to confirm the direction of DHA transport by FATP1 at the BBB, and in particular, to establish whether FATP1 is localized at the apical membrane or the basal membrane. We established an method to investigate the transporter localization in porcine brain capillary endothelial cells, based on a combination of plasma membrane fractionation and QTAP techniques without antibody (Kamiie et al. 2008; Kubo et al. 2015) , and found that FATP1 is preferentially expressed in the basal membrane in brain microvessels . In our present study, immunohistochemical analysis using antibody confirmed that FATP1 is preferentially expressed at the basal side in the BBB (Fig. 5) . Interestingly, however, transport experiments and metabolomic analysis using a FATP1-expressing cell line showed that FATP1 transports DHA in both directions, i.e., from extracellular to intracellular space, and from intracellular to extracellular space. This is consistent with a report that knockdown of FATP1 in primary human brain microvessel endothelial cells decreased oleic acid transport in both apical-to-basal and basal-to-apical directions (Mitchell et al. 2009 ). Nevertheless, DHA is actively incorporated into brain parenchymal cells, and therefore blood-to-brain transport would be favored in response to the utilization of DHA in the brain.
DHA is biosynthesized from a-linoleic acid in the liver. It has been reported that the efficacy of DHA biosynthesis in the liver was increased when the DHA concentration was reduced in the body (Rapoport and Igarashi 2009) , and DHA has been reported to facilitate insulin secretion via GPR40 in the pancreas (Itoh et al. 2003) . Based on these reports, we suggested that there was the homeostatic mechanism to transport DHA from blood to the brain via the following four steps: (i) DHA biosynthesis in the liver is facilitated in response to the DHA concentration in the body, (ii) DHA is transported to the pancreas via the blood circulation, (iii) insulin secretion is facilitated via GPR40 in the pancreas and (iv) DHA transport from blood to the brain is increased via the secreted insulin.
Insulin is secreted from pancreatic b-cells when the blood glucose level is elevated following food intake. The blood insulin level increases for 1-2 h after meals, and subsequently decreases to the basal level. In this study, the DHA uptake by endothelial cells was increased at 30 min after insulin treatment. Therefore, it is plausible that the supply of DHA to the brain via FATP1 would be effectively increased soon after meals due to the action of insulin secreted into blood. Insulin has various neuroprotective effects on the brain via insulin signaling (Zhao et al. 1999; Zhao and Alkon 2001; De Felice et al. 2009 ). Further, the impairment of insulin signaling in the brain is associated with the development of Alzheimer's disease (Wang et al. 2010; Holscher 2011 ). Indeed, a decrease of blood insulin level was reported to be involved in the pathogenesis of Alzheimer's disease (Wang et al. 2010; Holscher 2011) . It has been reported that dietary DHA ameliorates Alzheimer's disease (Hashimoto et al. 2005; Lim et al. 2005; Hooijmans et al. 2009) , and the brain level of DHA in patients with Alzheimer's disease is lower than that in healthy humans (Celik et al. 2002) . These results suggest that DHA supply across the BBB may be decreased as a result of impaired insulin signaling, and this could play a role in the pathogenesis of Alzheimer's disease.
The uptake of [ 3 H]-biotin in FATP1-expressing HEK293 cells were 1.7-2.8 fold and 1.6 fold compared with mock HEK293 cells, respectively ( Fig. 6a and b) . We believe that these differences involved FATP1-mediated transport. In the knock-down analysis of FATP1 in hCMEC/D3 cells, FATP1-mediated uptake accounts for 59.2-73.0% of total [ 14 C]-DHA uptake by the cells (Fig. 3) . Based on these results, FATP1 can contribute to the transport of taurine and biotin as well as DHA transport in hCMEC/D3 cells, which is a human brain microvessel endothelial model cell line. The expression level of FATP1 was found to be 2.08 fmol/lg protein in human brain capillaries in a previous report (Shawahna et al. 2011) , and similar to that of the whole cell fraction of hCMEC/D3 cells (4.87 fmol/lg protein, Table S1 ). Therefore, based on the protein expression level, FATP1 can contribute to the transport of taurine and biotin in human blood vessels as well as in vitro.
A decreased taurine level in the brain is associated with various neuronal disorders, including developmental retardation, hypotonia, seizure, anxiety, and hyperactivity disorder (Jin et al. 2005; Oja and Saransaari 2013) . Taurine is supplied to the brain via two routes: release from neurons in the brain and transport from blood across the BBB (Han et al. 1997; Kang et al. 2002) . In a rodent study, TauT was concluded to be responsible for taurine supply across the BBB (Kang et al. 2002) , but our recent study indicated that the human BBB does not express TauT . In contrast, FATP1 is consistently expressed at the BBB among animal species, including humans (Shawahna et al. 2011; Uchida et al. 2014; Kubo et al. 2015) . Since taurine is essential for proper functioning of the brain in all animal species (Oja and Saransaari 2013) , FATP1 may play a predominant role in taurine supply to the brain, rather than TauT, which shows substantial species differences in protein expression level at the BBB.
Biotin-responsive basal ganglia disease is a disorder that affects the nervous system presenting as external ophthalopathies, seizures, and confusion. This disease is characterized by episodic encephalopathy, often triggered by febrile illness. The gene mutations of SLC19A3 (thiamine transporter 2, THTR2) is associated with this disease, and biotin is given as a treatment and administration of a large amount of biotin is suggested to improve the disease, so this transporter is thought to transport biotin, and mutation of the SLC19A3 gene is thought to impair the transport of biotin and reduce the import of biotin from blood to the brain in patients (Zeng et al. 2005) . Nevertheless, biotin was subsequently shown not to be a substrate of SLC19A3 (Subramanian et al. 2006) . Instead, we recently suggested that SLC5A6 is mainly involved in the apical uptake of biotin from blood into the brain capillary endothelial cells , and our present findings support the idea that FATP1 also serves as a basal transporter for biotin. Further studies would be needed to clarify the biotin transport activities of SLC5A6 and FATP1 at the BBB in biotin-responsive basal ganglia disease. Such studies might uncover the cause of biotin-responsive basal ganglia disease and lead to the development of evidencebased therapy.
In conclusion, we have shown here that FATP1 mediates DHA transport in human brain capillary endothelial cells, and insulin stimulates this transport of DHA. We have also shown that FATP1 is responsible for the transport of taurine and biotin, as well as DHA. These findings should be helpful for understanding the homeostatic control mechanisms of DHA, taurine and biotin levels in the brain.
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